扩张型心肌病基因型与心律失常风险
本研究基于国际SHaRe注册队列,分析2660例基因分型成人扩张型心肌病(DCM)患者,按高致心律失常风险基因、低风险基因及基因阴性分层。高致心律失常风险基因P/LP变异者主要室性心律失常(MVA)、房颤、心衰及复合终点风险均升高,且在LVEF≥50%者中MVA风险仍升高;遗传检测可独立于年龄、性别和LVEF进行风险分层。
要点
- 高致心律失常风险基因P/LP变异者MVA风险显著升高(HR 3.25)。
- LVEF≥50%的高风险基因携带者MVA风险仍升高(HR 2.36)。
- 遗传检测有助于DCM心律失常和心衰的独立风险分层。
核心结论
- DCM患者中高致心律失常风险基因P/LP变异与MVA、房颤、心衰及复合终点风险升高相关,且独立于年龄、性别和LVEF。
- 遗传检测可对DCM的心律失常和心衰风险进行有力分层。
研究设计与样本
- 基于国际Sarcomeric Human Cardiomyopathy Registry(SHaRe)的多中心队列分析。
- 纳入2660例已基因分型的成人DCM患者(平均诊断年龄47±15岁,39.8%女性)。
主要发现
- 434例(16%)携带高致心律失常风险基因P/LP变异,451例(17%)携带低致心律失常风险基因变异,1775例(67%)为基因阴性。
- 与基因阴性者相比,高致心律失常风险基因P/LP变异者MVA风险升高(HR 3.25,95%CI 2.63-4.01)。
- 高致心律失常风险基因P/LP变异者房颤(HR 2.42,95%CI 1.96-2.98)、心衰(HR 2.46,95%CI 1.89-3.19)及复合终点(HR 1.97,95%CI 1.69-2.29)风险亦升高。
- 高致心律失常风险基因P/LP变异且LVEF≥50%者MVA风险(HR 2.36,95%CI 1.59-3.51)和复合终点风险(HR 1.63,95%CI 1.25-2.12)仍升高。
关键数值与推荐
- 高致心律失常风险基因包括LMNA、DSP、FLNC、RBM20、PLN、SCN5A、DES、TMEM43。
- 低致心律失常风险基因包括TTN、TNNT2、MYH7及其他基因。
- 风险估计均经年龄、性别和基线LVEF校正。
临床怎么用
- 对DCM患者应进行遗传检测,识别高致心律失常风险基因P/LP变异以指导猝死预防策略。
- LVEF保留的高风险基因携带者仍应警惕室性心律失常风险,不宜仅凭LVEF评估风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Dilated cardiomyopathy (DCM) presents with variable risk of life-threatening arrhythmias. Genetic diagnosis guides sudden death prevention strategies, but risk magnitude for arrhythmogenic genes remains unknown. This study leveraged the international Sarcomeric Human Cardiomyopathy Registry (SHaRe) to address this gap and improve risk stratification. METHODS: Effects of pathogenic/likely pathogenic (P/LP) variants in genes associated with DCM and ventricular arrhythmia on clinical events were analysed in DCM-SHaRe patients. Patients were stratified by presence of a P/LP variant in a high-arrhythmogenic risk gene (LMNA, DSP, FLNC, RBM20, PLN, SCN5A, DES, TMEM43), a low-arrhythmogenic risk gene (TTN, TNNT2, MYH7, others), or gene-elusive. Outcomes included age-, sex-, and baseline left ventricular ejection fraction (LVEF)-adjusted risk of major ventricular arrhythmia (MVA), atrial fibrillation (AF), heart failure (HF), death, and their composite. RESULTS: Among 2660 genotyped adults with DCM (mean diagnosis age 47 ± 15 years, 39.8% female), 434 (16%) had P/LP variants in high-arrhythmogenic genes, 451 (17%) in low-arrhythmogenic genes, and 1775 (67%) were gene-elusive. Compared with gene-elusive patients, patients with high-arrhythmogenic P/LP variants showed increased MVA [hazard ratio (HR) 3.25, 95% confidence interval (CI) 2.63-4.01], AF (HR 2.42, 95% CI 1.96-2.98), HF (HR 2.46, 95% CI 1.89-3.19), and composite (HR 1.97, 95% CI 1.69-2.29) risk, which remained significant after adjusting for age, sex, and LVEF. Patients with high-arrhythmogenic P/LP variants and LVEF ≥ 50% maintained increased MVA (HR 2.36, 95% CI 1.59-3.51) and composite (HR 1.63, 95% CI 1.25-2.12) risk. CONCLUSIONS: Genetic testing enables powerful risk stratification for arrhythmias and HF in DCM independent of age, sex, or LVEF.
引用
- Padalia K, Fornaro A, Claggett B, et al. Genotype and arrhythmic risk in dilated cardiomyopathy. Eur Heart J. 2026. PMID: 42864989. doi:10.1093/eurheartj/ehag648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。